XLO News and Press, Xilio Therapeutics Inc.

2024-05-14 13:54:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xilio Therapeutics (NASDAQ: XLO ) just reported results for the first quarter of 2024. Xilio Therapeutics reported earnings per share of -59 cents. This was below the anal...

2024-05-14 09:22:39 ET More on Xilio Therapeutics Xilio Therapeutics reports Q4 results Xilio stock jumps on Gilead Sciences license deal Seeking Alpha’s Quant Rating on Xilio Therapeutics Historical earnings data for Xilio Therapeutics Financi...

Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-a...

2024-04-04 16:57:58 ET Summary Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf T...

2024-04-02 08:37:57 ET More on Pre-market losers & stocks. Hut 8 Mining Corp. (HUT) Q4 2023 Earnings Call Transcript From Bull To Bear: Recent Events Drove Me To Exit My Position In HUT 8 Hut 8 Post-Merger Comprehensive Thesis: JCapital Research Might Be Right ...

2024-04-01 16:54:08 ET More on Xilio Therapeutics Xilio stock jumps on Gilead Sciences license deal Xilio Therapeutics announces $11.3 million private placement equity financing Seeking Alpha’s Quant Rating on Xilio Therapeutics Historical earnings dat...

A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and ...

2024-04-01 12:57:59 ET More on Mid-day movers & stocks. Meta Materials total Q4 revenue up 55% y/y Meta Materials announces $1M civil penalty to settle SEC investigation Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for...

2024-04-01 10:00:18 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...